iSpecimen prices 5.7M shares at 70c in underwritten public offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 24 2025
0mins
Public Offering Announcement: iSpecimen has priced an underwritten public offering of 5,714,283 shares at $0.70 per share, aiming for approximately $4M in gross proceeds before expenses, with the closing expected on July 25, 2025.
Use of Proceeds: The funds will be allocated for marketing services, a milestone payment to Sales Stack Solutions Corp., and general working capital. WestPark Capital is the Sole Book-Runner for the offering.
Analyst Views on ISPC
About ISPC
iSpecimen Inc. is a technology-driven company. The Company addresses a critical challenge, which focuses on connecting life science researchers who need human biofluids, tissues, and living cells (biospecimens) for their research. The Company’s iSpecimen Marketplace platform is designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery. Its technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. In addition to providing the technology platform to connect researchers and healthcare providers, the Company handles all marketing, sales, contracting, and compliance functions across both sides of the marketplace. The iSpecimen Marketplace technology comprises four functional areas: search, workflow, data and administrative, compliance and reporting.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
